Arsenic trioxide is a chemotherapy drug that turned one of the deadliest forms of blood cancer into one of the most curable. Approved by the FDA in 2000 for acute promyelocytic leukemia (APL), it has produced complete remission rates approaching 100 percent when combined with another agent, retinoic acid. The compound’s story is one of medicine’s stranger turnarounds: a substance synonymous with poisoning, used therapeutically for millennia, abandoned for decades, and then revived by Chinese physicians who recognized its remarkable ability to destroy leukemia cells while leaving most healthy tissue intact.
From Ancient Remedy to Abandoned Drug to Cancer Breakthrough
Arsenic has been used in medicine for over 2,400 years, making its therapeutic history almost as long as recorded medicine itself.1PubMed. History of the development of arsenic derivatives in cancer therapy In the eighteenth century, a physician named Thomas Fowler developed a potassium bicarbonate-based solution of arsenic trioxide that became one of the most widely prescribed medicines of its era. Fowler’s solution was used for everything from fevers to skin conditions, and by 1878 it had been reported to reduce white blood cell counts, hinting at its potential in blood cancers.2The Oncologist. Introduction: The History of Arsenic Trioxide in Cancer Therapy Through the 1930s, arsenic was a recognized treatment for chronic myelogenous leukemia.
Then it fell out of favor. The mid-twentieth century brought radiation therapy and cytotoxic chemotherapy, both of which seemed more sophisticated. Concerns about chronic arsenic toxicity and its known carcinogenicity when people are exposed to it over long periods made physicians increasingly uncomfortable prescribing it. By the mid-1990s, the only remaining medical use for an arsenic compound was treating trypanosomiasis, a parasitic infection.3PubMed. History of the development of arsenic derivatives in cancer therapy
The revival began in China in the 1970s. Physicians in Harbin started administering arsenic trioxide to patients with APL, a particularly aggressive leukemia that was often fatal within weeks of diagnosis. The results were striking enough that Chinese researchers published a series of reports showing a high proportion of patients achieving remission. Western researchers took notice, launched their own clinical trials, and by September 2000, the FDA had approved arsenic trioxide (marketed as Trisenox) for patients with relapsed or refractory APL.4The Oncologist. Introduction: The History of Arsenic Trioxide in Cancer Therapy
How It Works Against Leukemia Cells
Arsenic trioxide attacks APL cells through two simultaneous pathways, which is part of why it works so well. First, it degrades a fusion protein called PML-RARα, which is the molecular driver of APL. This protein is produced by a chromosomal abnormality unique to this leukemia, and when arsenic trioxide breaks it down, the leukemia cells lose the signal that kept them locked in an immature, rapidly dividing state. Freed from that signal, many of them mature into normal white blood cells, a process called differentiation.
Second, arsenic trioxide triggers apoptosis, the cell’s built-in self-destruct program. It does this largely by generating reactive oxygen species (ROS), essentially flooding the cell with chemically reactive molecules that damage mitochondria and DNA. Studies in leukemia cell lines have shown that arsenic trioxide ramps up ROS production, depletes the cell’s protective antioxidant glutathione, collapses the electrical potential across mitochondrial membranes, and activates caspase enzymes that dismantle the cell from within.5PubMed Central. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells The effect is dose-dependent: higher concentrations cause more oxidative damage and more cell death.
This dual mechanism, forcing cancer cells to either grow up or die, is unusual in oncology. Most chemotherapy drugs rely on a single strategy, typically just killing dividing cells indiscriminately. Arsenic trioxide is more selective because its primary target, the PML-RARα fusion protein, exists only in APL cells. That selectivity explains why a compound notorious for poisoning can be therapeutic at the right dose in the right disease.
Clinical Results That Changed APL Treatment
The clinical evidence for arsenic trioxide in APL is as strong as anything in cancer medicine. A landmark trial published in the New England Journal of Medicine compared two treatment approaches for newly diagnosed APL: retinoic acid combined with arsenic trioxide (ATRA-ATO) versus retinoic acid combined with conventional chemotherapy (ATRA-chemo). Every one of the 77 evaluable patients in the ATRA-ATO group achieved complete remission, a rate of 100 percent. The ATRA-chemo group achieved 95 percent. After a median follow-up of about three years, the two-year event-free survival rate was 97 percent with ATRA-ATO compared to 86 percent with ATRA-chemo, and overall survival was also better in the arsenic-containing arm.6PubMed. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Those numbers are remarkable for any cancer, let alone a leukemia that was once rapidly fatal. And the arsenic-based regimen was not just more effective; it was easier on patients. The ATRA-ATO combination caused less blood count suppression and fewer infections than chemotherapy, though it did produce more liver-related side effects.7PubMed. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia For many patients, particularly those who are older or have other health conditions, avoiding the severe immune suppression that comes with traditional chemotherapy is a major advantage.
Arsenic trioxide is effective across all stages of APL, including in patients who have relapsed after prior treatment or who have not responded to other therapies.8PubMed Central. A review of arsenic trioxide and acute promyelocytic leukemia This versatility has made the ATRA-ATO combination the standard of care in many countries, effectively replacing chemotherapy-heavy regimens for most APL patients.
Results in Children
Pediatric APL presents a particular challenge because children have decades of life ahead and are especially vulnerable to the long-term effects of chemotherapy, particularly the heart damage caused by anthracycline drugs. A Children’s Oncology Group trial tested whether incorporating arsenic trioxide into consolidation therapy could allow doctors to lower the anthracycline dose without sacrificing outcomes. The results were encouraging: three-year overall survival was 94 percent, and event-free survival was 91 percent. Among standard-risk patients, overall survival reached 98 percent. The relapse rate from the end of the first consolidation cycle was only about 4 percent at three years.9Journal of Clinical Oncology. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children’s Oncology Group Phase III Historically Controlled Trial AAML0631
Reducing the anthracycline burden in children is meaningful well beyond the immediate cancer fight. Anthracyclines can cause permanent heart muscle damage that may not show up until years or even decades later. By substituting arsenic trioxide for some of that exposure, clinicians can maintain excellent cure rates while potentially sparing children from cardiac complications down the road.
Side Effects and Safety Concerns
Arsenic trioxide is far safer at therapeutic doses than its reputation suggests, but it does carry real risks that require monitoring. The most important is its effect on the heart’s electrical system. The drug can prolong the QT interval, a measurement on an electrocardiogram that reflects how long it takes the heart’s ventricles to reset between beats. A prolonged QT interval can, in rare cases, trigger a dangerous arrhythmia called torsades de pointes, reported in roughly 1 percent of patients.10Acta Pharmacologica Sinica / PubMed Central. Arsenic trioxide: safety issues and their management
The mechanism behind this cardiac effect is more complicated than with most QT-prolonging drugs. Arsenic trioxide blocks two potassium channels involved in heart cell repolarization (IKr and IKs), which would be expected to lengthen the QT interval. But it simultaneously activates a third potassium channel (IK-ATP) that works to maintain normal repolarization.11PubMed. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents These opposing effects explain why QT prolongation with arsenic trioxide is variable from patient to patient: the balance between channel blockade and channel activation differs depending on underlying heart health and electrolyte levels. Patients with low potassium or magnesium are at higher risk, which is why electrolyte monitoring and correction are standard practice during treatment.
Oral formulations of arsenic trioxide produce lower peak plasma arsenic levels than intravenous infusion, which translates to less QT prolongation and a more favorable cardiac safety profile overall.12Acta Pharmacologica Sinica / PubMed Central. Arsenic trioxide: safety issues and their management Oral arsenic trioxide has become an important option in settings where intravenous administration is less practical or where cardiac risk needs to be minimized.
The other major complication is differentiation syndrome, which occurs when a flood of maturing leukemia cells provokes an intense inflammatory response. Symptoms can include unexplained fever, difficulty breathing, weight gain from fluid retention, and pleural or pericardial effusions. In one large study of nearly 300 newly diagnosed APL patients treated with single-agent arsenic trioxide, about 47 percent developed some degree of differentiation syndrome, with the severity correlating to how rapidly and how high white blood cell counts rose during treatment.13SpringerLink / Annals of Hematology. Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide Differentiation syndrome can be life-threatening if untreated, but it responds well to corticosteroids when caught early. That’s why oncologists monitor white blood cell counts closely and often initiate steroid treatment preemptively.
How the Body Processes Arsenic Trioxide
Once arsenic trioxide enters the bloodstream, it is rapidly metabolized, primarily in the liver. An enzyme called AS3MT (arsenic methyltransferase) converts it into methylated arsenic metabolites. This conversion is not just detoxification; it appears to be functionally important for the drug’s anti-leukemic effect. The methylated metabolites contribute to a balance between directly killing cancer cells and pushing them toward differentiation, and this balance is thought to be a key reason the treatment works so well against APL.14PubMed. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts
Genetic variation in the AS3MT gene may influence how individual patients metabolize the drug. Researchers have identified numerous single-nucleotide polymorphisms in AS3MT, and monitoring arsenic methylation patterns in patients has been proposed as a way to optimize dosing and predict who might experience more side effects.15PubMed Central. Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide In fatal poisoning cases, the trivalent inorganic form of arsenic predominates in organs, with relatively less of the methylated metabolites, suggesting that the body’s ability to methylate arsenic is a crucial buffer between therapeutic benefit and toxicity.16Clinical Chemistry. Arsenic Speciation in Human Organs following Fatal Arsenic Trioxide Poisoning—A Case Report
The p53 Discovery and What It Could Mean for Other Cancers
In 2020, researchers reported a finding that could substantially expand arsenic trioxide’s usefulness beyond APL. The tumor suppressor protein p53, sometimes called the “guardian of the genome,” is the most commonly mutated protein in human cancers. When p53 is mutated, it often loses its ability to fold correctly and can no longer perform its normal job of stopping damaged cells from dividing. Arsenic trioxide was found to bind to a previously unknown site on certain mutant forms of p53, stabilizing the protein’s structure and restoring its ability to function as a tumor suppressor.17Cancer Cell. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Crystal structures showed that arsenic coordinates with three cysteine residues in the DNA-binding domain of the mutant protein, essentially acting as molecular glue that holds the misfolded protein in a functional shape. In mouse models, arsenic trioxide reactivated mutant p53 and suppressed tumor growth.18Cancer Cell. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site Subsequent work in a mouse model mimicking Li-Fraumeni syndrome, a hereditary condition driven by germline p53 mutations, showed that arsenic trioxide treatment extended survival.19Cell Death & Disease. Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse
There are caveats. Not all p53 mutations respond equally. Research examining 17 frequently observed temperature-sensitive p53 mutants found that arsenic trioxide only rescued mild mutants that retained some baseline activity. The rescue effect was also rapidly reversible and was counteracted by the cell’s own antioxidant defenses, particularly glutathione. Blocking glutathione production enhanced the drug’s ability to reactivate p53 and sustained the effect after the drug was removed.20PubMed Central. Synergistic rescue of temperature sensitive p53 mutants by hypothermia and arsenic trioxide This means that any future clinical application of arsenic trioxide for p53-mutant solid tumors will likely require careful patient selection based on the specific mutation involved, and possibly combination with agents that lower cellular glutathione levels.
Exploring Use in Other Cancers
The success in APL naturally prompted researchers to test arsenic trioxide against other malignancies. Multiple myeloma, another blood cancer, was an early target. Preclinical work showed that arsenic trioxide at concentrations achievable in patients could kill myeloma cells, including drug-resistant ones, through caspase-9 activation. It also disrupted the protective relationship between myeloma cells and the bone marrow environment by reducing their ability to attach to supportive stromal cells and by blocking the secretion of growth-promoting signals like interleukin-6 and VEGF.21Molecular Cancer Therapeutics. Arsenic Trioxide Inhibits Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment A small phase II trial in patients with relapsed, heavily pretreated myeloma produced responses in a handful of patients, enough to justify further investigation but far from the transformative results seen in APL.22PubMed. Clinical activity of arsenic trioxide for the treatment of multiple myeloma
Liver cancer has also attracted interest. In an animal model, arsenic trioxide delivered via microspheres during a procedure called transarterial chemoembolization suppressed tumor growth, reduced the formation of new blood vessels feeding the tumor, and extended survival compared to other delivery methods.23PubMed Central. Antitumor properties of arsenic trioxide-loaded CalliSpheres microspheres by transarterial chemoembolization in VX2 liver tumor rabbits More recently, laboratory and mouse studies have shown that arsenic trioxide can enhance the effectiveness of PD-1 immune checkpoint inhibitors in hepatocellular carcinoma by triggering a form of cancer cell death that alerts the immune system, essentially making the tumor more visible to immune attack.24Wiley Online Library. Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway
None of these applications beyond APL are clinically established. Solid tumors are fundamentally harder to treat with arsenic trioxide because the drug does not concentrate in solid tissue the way it does in the blood, and it lacks a specific molecular target in most solid cancers comparable to PML-RARα in APL. Still, the p53-reactivation findings and the immunotherapy-combination data have reinvigorated interest.
New Ways to Deliver the Drug
One of the biggest obstacles to using arsenic trioxide in solid tumors is getting enough of it into the tumor without poisoning the rest of the body. Nanoparticle-based delivery systems are being developed to solve this problem. The concept is to package arsenic trioxide inside tiny carriers that accumulate preferentially in tumor tissue, release the drug there, and minimize exposure to healthy organs.
Several approaches have reached the laboratory stage. Mesoporous silica nanoparticles decorated with a targeting peptide have been engineered to deliver arsenic trioxide specifically to triple-negative breast cancer cells, a subtype with few treatment options.25PubMed. Targeted Mesoporous Silica Nanoparticles Delivering Arsenic Trioxide with Environment Sensitive Drug Release for Effective Treatment of Triple Negative Breast Cancer For liver cancer, polymer nanoparticles coated with a sugar derivative that binds to receptors on liver cancer cells have shown effective tumor inhibition in animal studies while causing no detectable kidney or liver toxicity, a key concern with free arsenic trioxide.26PubMed. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced These systems are designed to release the drug in a controlled fashion: an initial burst to reach a therapeutic concentration, followed by a sustained release to maintain it.27PubMed Central. Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy
All of this remains preclinical. Nanoparticle drug delivery is a field full of promising animal data that has historically struggled to translate into human treatments. But for a drug like arsenic trioxide, where the therapeutic window between effective dose and toxic dose is narrow, smarter delivery could be what opens the door to treating cancers beyond APL.
When Arsenic Trioxide Stops Working
Even in APL, arsenic trioxide does not cure every patient. Understanding why some patients relapse has been an active area of research. One straightforward hypothesis was that mutations in the PML gene’s B2 domain, the region arsenic trioxide binds to, would prevent the drug from degrading the fusion protein. Targeted sequencing found B2 domain mutations in about 15 percent of relapsed patients, but these mutations were not consistently associated with resistance, suggesting they are only part of the story.28PLoS ONE. Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance
Gene expression profiling comparing newly diagnosed and relapsed patients revealed broad differences across hundreds of genes involved in cell adhesion, immune regulation, and stem cell biology. Relapsed patients showed significantly increased expression of CD34, a marker associated with primitive, stem-like leukemia cells. There was also laboratory evidence that the bone marrow microenvironment itself shielded these cells from the drug’s effects, a phenomenon called environment-mediated drug resistance.29PLoS ONE. Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance The emerging picture is that relapse after arsenic trioxide is probably not driven by one mutation but by a combination of factors, including expansion of the most primitive leukemia-initiating cells and protection from the bone marrow niche.
Cost and Accessibility
One often overlooked advantage of arsenic trioxide-based treatment is its cost. Because arsenic trioxide is a simple inorganic compound, generic versions are inexpensive to manufacture. A study comparing the cost of APL treatment with generic arsenic trioxide versus conventional chemotherapy found that the mean treatment cost was roughly $8,500 for the arsenic-based regimen compared to about $22,600 for chemotherapy. Over a five-year horizon modeled with a Markov analysis, the gap persisted: approximately $11,100 versus $17,900.30PubMed Central. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide The savings came not just from drug cost but from reduced hospitalization and less need for antibiotics and antifungal drugs, reflecting the lower infection risk compared to chemotherapy.
This cost profile matters most in low- and middle-income countries, where APL remains disproportionately fatal because conventional chemotherapy regimens require extensive supportive care infrastructure: transfusion services, isolation rooms, broad-spectrum antimicrobials. An arsenic trioxide-based regimen that can be given without much of that infrastructure has the potential to make a curable disease actually cured in settings where it currently is not. Oral formulations further simplify logistics by eliminating the need for intravenous access and extended hospital stays, making outpatient treatment feasible even in resource-limited clinics.